Preview this article: A hundred days into the coronavirus disease (COVID-19) pandemic, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/25/14/eurosurv-25-14-1-1.gif

Preview this article: 20 years of communicating facts and figures, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/21/48/eurosurv-21-30415-1-1.gif

Preview this article: Complexities in assessing the effectiveness of inactivated influenza vaccines, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/18/7/art20403-en-1.gif

Preview this article: Our first impact factor, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/17/27/art20214-en-1.gif

Preview this article: The Eurosurveillance reader survey – what’s next?, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/16/45/art20014-en-1.gif

Preview this article: Eurosurveillance – keeping an eye on infectious diseases, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/15/1/art19452-en-1.gif

In September 2010, the 53 member states of the World Health Organization (WHO) European Region met in Moscow, Russia, and adopted a resolution to renew their commitment to the elimination of measles and rubella and the prevention of congenital rubella syndrome by 2015 [1]. While great progress has been made towards measles and rubella elimination in the Region, with some countries interrupting endemic transmission of one or both of the diseases, the public health community had to come to terms with the fact that 2010 will not be the year when measles and rubella elimination is achieved in the European Region. As experience from the Americas shows, it is technically feasible to eliminate measles with a defined strategy [2]. So why has the goal not yet been reached in Europe?

Preview this article: The European Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE) - selected papers from the conference 2008, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/14/43/art19377-en-1.gif

Preview this article: Accepted for the impact factor – what is the impact of Eurosurveillance?, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/14/38/art19339-en-1.gif

From this issue of Eurosurveillance, the two previous electronic releases (weekly and monthly) of the journal have been merged into one. The new Eurosurveillance is published every Thursday, with rapid updates on major public health events and news items alongside longer scientific articles and reviews. At the same time we are updating our editorial policy (http://www.eurosurveillance.org/editorial_policy/index.asp) and reviewing the types of articles (http://www.eurosurveillance.org/authors/index.asp) to better reflect our commitment to covering all aspects of epidemiology, prevention and control of communicable diseases from a European perspective.

Although vaccine-preventable, rabies remains a worldwide-occurring disease of major public health concern. Globally, rabies is responsible for about 55,000 human deaths per year, mainly in Asia and Africa, and 30-50% of the cases are in children, most often following an infection transmitted through the bite of a rabid dog.

From 1 May, a new Health Communication Unit (HCU) has been established in the European Centre for Disease Prevention and Control (ECDC).

The 2006 FIFA World Cup football tournament began in Germany on 9 June

On 16 February 2005, the Deutsche Stiftung Organtransplantation (German Foundation for Organ Transplantation, http://www.dso.de/) announced possible rabies cases in three of six patients who received organs from a donor who died in late December 2004